Merck has a clearly scheduled earnings catalyst now. The company said it will hold its second-quarter 2026 sales and earnings conference call at 9:00 a.m. Eastern Time on Tuesday, August 4, 2026. For options traders, that matters because MRK is heading into the report with several real cross-currents already visible in the first-quarter numbers.
Merck’s first quarter showed solid sales growth in oncology, Animal Health, and newer launches such as Winrevair, but the company still reported a GAAP and non-GAAP loss per share because of a large charge tied to the acquisition of Cidara Therapeutics. That makes August 4 more interesting than a plain large-cap pharma calendar event. The market already knows Merck has strong franchises. The real question is whether the next update keeps the operating picture strong enough to outweigh Gardasil pressure, acquisition charges, and broader portfolio-transition concerns.
This is not financial advice. Options trading involves risk and is not suitable for all investors.
What Merck has already confirmed
The confirmed facts heading into the report are specific enough to frame the whole event.
- Merck said it will hold its second-quarter 2026 sales and earnings conference call at 9:00 a.m. ET on Tuesday, August 4, 2026.
- In the first quarter of 2026, Merck reported worldwide sales of USD 16.3 billion, up 5% year over year, or 3% excluding foreign exchange.
- KEYTRUDA and KEYTRUDA QLEX sales were USD 8.0 billion, up 12% year over year.
- WINREVAIR sales were USD 525 million, up 88% year over year.
- Animal Health sales were USD 1.8 billion, up 13% year over year.
- GARDASIL and GARDASIL 9 sales were USD 1.069 billion, down 19% year over year.
- GAAP loss per share was USD 1.72, and non-GAAP loss per share was USD 1.28, with both figures including a USD 3.62 per share charge tied to the Cidara acquisition.
- Merck’s full-year 2026 outlook after the first quarter called for worldwide sales of USD 65.8 billion to USD 67.0 billion and non-GAAP EPS of USD 5.04 to USD 5.16. The outlook did not include the impact of the planned Terns Pharmaceuticals acquisition, which Merck said would result in an approximately USD 5.8 billion one-time charge when it closes.
Those details matter because they show that Merck is not trading on one simple drug headline. It is trading on whether its strongest growth engines are large enough to carry the broader franchise while several other lines are under pressure or being reshaped.
Why This Matters For Options Traders
Merck’s August 4 report matters for options traders because the market has to weigh operating strength against noise from acquisitions and weaker vaccine demand.
If investors focus on the stronger side of the story, they can point to Keytruda growth, rapid Winrevair uptake, and continued Animal Health momentum. If investors focus on the weaker side, they can point to Gardasil pressure, acquisition charges, and the risk that portfolio repair is getting more expensive at the same time some older franchises are slowing.
That mix can matter around earnings because a stock with competing narratives does not need a dramatic revenue miss to move. It may only need one side of the debate to become more believable after management updates the outlook.
The main things MRK options traders should actually watch
1. Whether Keytruda and newer launches still dominate the story
Merck’s first-quarter growth was heavily anchored by oncology and newer products. Keytruda and Keytruda QLEX sales reached USD 8.0 billion, while Winrevair reached USD 525 million.
That matters because it shows where the market will likely look first on August 4. If Merck keeps showing that Keytruda remains durable and newer launches are scaling well enough to widen the growth base, investors may stay constructive even if some legacy categories remain softer.
2. Whether Gardasil pressure still drags on the total picture
Gardasil and Gardasil 9 sales fell 19% in the first quarter to USD 1.069 billion, with Merck citing lower demand in China and lower sales in Japan and the United States for specific purchasing-pattern reasons.
That matters because vaccine weakness is not just a side note. If the market thinks Gardasil pressure is staying deep or persistent, it can become a larger part of the earnings debate even while oncology remains strong.
3. Whether traders can separate one-time charges from the operating baseline
Merck’s first-quarter EPS looked weak because of the Cidara acquisition charge. The company also warned that the planned Terns acquisition would create another large one-time charge when it closes.
That means August 4 is partly a quality-of-earnings event. Traders need to decide whether the market is becoming more willing to look through these charges as portfolio-building investments, or whether the accumulation of deal costs is starting to dilute confidence in the cleaner operating story.
4. Whether the full-year frame still looks stable
After the first quarter, Merck narrowed and raised the midpoint of its full-year worldwide sales range and narrowed and raised its expected non-GAAP EPS range. That was a constructive signal.
The practical question now is whether management can keep that tone intact on August 4. If the company holds the line on the full-year frame while the core franchises still look healthy, the event may reinforce the resilience case. If the commentary starts sounding more cautious, the market may react more to uncertainty than to the historical strength of the franchise.
What traders may misunderstand
Merck is only a Keytruda stock
Too simple. Keytruda is central, but Winrevair, Animal Health, Gardasil, and newer launches all matter to how the market reads the earnings mix.
The first-quarter EPS loss means the operating story is broken
Not necessarily. Merck’s first-quarter release showed that sales growth remained healthy even while acquisition charges pushed reported EPS into a loss.
A raised midpoint last quarter guarantees another easy quarter
No. Guidance can still be challenged by weaker category trends, acquisition noise, or a change in management tone.
Options pricing can tell readers where MRK will go after earnings
No. Options can price uncertainty around the event, but they do not provide a clean directional forecast.
Bottom line
Merck’s August 4, 2026 earnings event matters because the company is trying to show that its strongest businesses are still powerful enough to carry the broader franchise through a period of portfolio change. In the first quarter, sales rose to USD 16.3 billion, Keytruda reached USD 8.0 billion, Winrevair reached USD 525 million, and Animal Health reached USD 1.8 billion, but Gardasil fell and acquisition charges pulled EPS into a loss.
For options traders, the useful question is not whether Merck is a good company in general. It is whether the August 4 update makes the operating baseline look more durable and more investable than the market currently assumes, especially with vaccine pressure and acquisition noise still in the picture. That is the real setup into the event. This is not financial advice.
Sources
- Merck Investor Relations, “Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4” (plain-text URL):
https://www.merck.com/news/merck-to-hold-second-quarter-2026-sales-and-earnings-conference-call-aug-4/ - Merck Investor Relations, “Q2 2026 Earnings Call” event page (plain-text URL):
https://www.merck.com/events/q2-2026-earnings-call/ - Merck Investor Relations, “Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones” (plain-text URL):
https://www.merck.com/news/merck-co-inc-rahway-n-j-usa-announces-first-quarter-2026-financial-results-highlights-significant-regulatory-approvals-and-clinical-milestones/ - Merck first-quarter 2026 earnings presentation PDF (plain-text URL):
https://www.merck.com/wp-content/uploads/sites/124/2026/04/1Q26-Merck-Earnings-Presentation.pdf
